Challenging your AAV productivity and packaging efficiencies through a validated platform

AAV transient and stable cell line platforms represent a leap into next-generation technologies that are set to drive gene therapy commercialization. Selecting the right manufacturing approach for AAV production is key to meeting productivity and scalability goals. Through case studies and data, we explore strategies to meet productivity targets efficiently and insights into achieving superior and scalable AAV production. 


Here, we will provide an overview of novel AAV transient transfection and stable producer cell line platforms designed to optimize AAV yields and process efficiency. We will present plasmid and cell engineering approaches to enhance these aspects in HEK293 cell line platforms. A method to develop a high-performing, helper virus-free, suspension HEK293-based AAV stable producer cell line platform will be outlined. Development and implementation of innovative analytics to better understand and improve AAV processes will be discussed. These technologies will be made available to the wider scientific community under a research license, or via Lonza’s CDMO service offerings.